Evidence map›Paper›PMID 25204288›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2014

Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Nishant S Gandhi, Rakesh K Tekade, Mahavir B Chougule

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed
20.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 391 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Nishant S GandhiDepartment of Pharmaceutical Science, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, HI, USA.
Rakesh K TekadeDepartment of Pharmaceutical Science, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, HI, USA; Preclinical Nuclear Imaging Laboratory, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 USA.
Mahavir B ChouguleDepartment of Pharmaceutical Science, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, HI, USA; Natural Products and Experimental Therapeutics Program, University of Hawaii Cancer Center, Honolulu, HI, USA. Electronic address: mahavir@hawaii.edu.
University of Hawaii at Hilo · USUniversity of Hawaii Cancer Center

Funding

The mode-of-action for pheromone-induced paralysis in Pristionchus pacificusSC3GM105579 · NIGMS · CALIFORNIA STATE UNIVERSITY NORTHRIDGE · PI HONG, RAY L · 2013 to 2020
$870k
Targeted Combination Therapy for Lung CancerSC3GM109873 · NIGMS · UNIVERSITY OF HAWAII AT HILO · PI CHOUGULE, MAHAVIR B · 2014 to 2016
$268k
NIGMS NIH HHS SC3 GM105579NIGMS NIH HHS SC3 GM109873
6 · The paper itself

Abstract

Chemotherapeutic agents have certain limitations when it comes to treating cancer, the most important being severe side effects along with multidrug resistance developed against them. Tumor cells exhibit drug resistance due to activation of various cellular level processes viz. activation of drug efflux pumps, anti-apoptotic defense mechanisms, etc. Currently, RNA interference (RNAi) based therapeutic approaches are under vibrant scrutinization to seek cancer cure. Especially small interfering RNA (siRNA) and micro RNA (miRNA), are able to knock down the carcinogenic genes by targeting the mRNA expression, which underlies the uniqueness of this therapeutic approach. Recent research focus in the regime of cancer therapy involves the engagement of targeted delivery of siRNA/miRNA in combinations with other therapeutic agents (such as gene, DNA or chemotherapeutic drug) for targeting permeability glycoprotein (P-gp), multidrug resistant protein 1 (MRP-1), B-cell lymphoma (BCL-2) and other targets that are mainly responsible for resistance in cancer therapy. RNAi-chemotherapeutic drug combinations have also been found to be effective against different molecular targets as well and can increase the sensitization of cancer cells to therapy several folds. However, due to stability issues associated with siRNA/miRNA suitable protective carrier is needed and nanotechnology based approaches have been widely explored to overcome these drawbacks. Furthermore, it has been univocally advocated that the co-delivery of siRNA/miRNA with other chemodrugs significantly enhances their capability to overcome cancer resistance compared to naked counterparts. The objective of this article is to review recent nanocarrier based approaches adopted for the delivery of siRNA/miRNA combinations with other anticancer agents (siRNA/miRNA/pDNA/chemodrugs) to treat cancer.

Indexed as

NanoparticlesAngiogenesis InhibitorsAnimalsAntineoplastic AgentsDrug CarriersDrug Delivery SystemsHumansMicroRNAsNanotechnologyNeoplasmsRNA, Small InterferingAngiogenesis InhibitorsAntineoplastic AgentsDrug CarriersMicroRNAsRNA, Small InterferingCancerClinical trialCombination therapymiRNANanotechnologysiRNA

Identifiers

PMID25204288
PMCPMC4254052
OpenAlexW2010731545

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.